Cargando…

A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors

Purpose BI 831266 is a potent, selective, low-molecular-weight inhibitor of Aurora kinase B. This trial aimed to determine the maximum tolerated dose (MTD) of BI 831266 in patients with advanced solid tumors (NCT00756223; EudraCT 2008-001631-36; 1257.1). Methods BI 831266 (4–130 mg) was administered...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dittrich, Christian, Fridrik, Michael A., Koenigsberg, Robert, Lee, Chooi, Goeldner, Rainer-Georg, Hilbert, James, Greil, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2014
Materias:	Phase I Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387274/ https://www.ncbi.nlm.nih.gov/pubmed/25529193 http://dx.doi.org/10.1007/s10637-014-0201-7

Ejemplares similares

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
por: Naing, Aung, et al.
Publicado: (2013)

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
por: Kroschinsky, Frank, et al.
Publicado: (2020)

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
por: Steeghs, Neeltje, et al.
Publicado: (2010)

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study
por: Blais, Normand, et al.
Publicado: (2013)

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
por: Smith, David C., et al.
Publicado: (2018)

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
por: Adjei, Alex A., et al.
Publicado: (2016)

Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
por: Doi, Toshihiko, et al.
Publicado: (2020)

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors
por: Denlinger, Crystal S., et al.
Publicado: (2021)

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
por: Gordon, Michael S., et al.
Publicado: (2012)

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
por: Pant, Shubham, et al.
Publicado: (2013)

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
por: Danilov, Alexey V., et al.
Publicado: (2021)

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
por: Marshall, John, et al.
Publicado: (2012)

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
por: von Mehren, Margaret, et al.
Publicado: (2014)

A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Balzarotti, Monica, et al.
Publicado: (2021)

A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
por: Mross, Klaus, et al.
Publicado: (2016)

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies
por: Cirkel, Geert A., et al.
Publicado: (2016)

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
por: Kelly, Kevin R., et al.
Publicado: (2013)

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
por: LoRusso, Patricia, et al.
Publicado: (2013)

Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer
por: Gustavsson, Bengt, et al.
Publicado: (2015)

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
por: Keizer, Ron J., et al.
Publicado: (2011)

A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma
por: Yau, Thomas, et al.
Publicado: (2012)

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer
por: Leary, Alexandra, et al.
Publicado: (2018)

Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
por: Kondo, Shunsuke, et al.
Publicado: (2020)

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies
por: Yoh, Kiyotaka, et al.
Publicado: (2016)

A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
por: Davis, S. Lindsey, et al.
Publicado: (2019)

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2009)

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
por: Stathis, Anastasios, et al.
Publicado: (2018)

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects
por: Halstenson, C. E., et al.
Publicado: (2016)

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
por: Awada, Ahmad, et al.
Publicado: (2015)

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer
por: Pili, Roberto, et al.
Publicado: (2014)

Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors
por: Mizugaki, Hidenori, et al.
Publicado: (2016)

Pharmacokinetic study of aldoxorubicin in patients with solid tumors
por: Mita, Monica M., et al.
Publicado: (2014)

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors
por: Takahashi, Toshiaki, et al.
Publicado: (2012)

Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors
por: Nijenhuis, Cynthia M., et al.
Publicado: (2016)

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vsouukg2c93uthlobsbj2a0bce